Indian pharma cos applaud US FDA's strong stance on safety reporting in BA/BE studies: Nandita Vijayasimha, Bengaluru Monday, December 22, 2025, 08:00 Hrs [IST] Indian pharmaceuti ...
Pharma regulators and the industry leaders are aligned in emphasizing that bioavailability and bioequivalence (BA/BE) studies remain a non-negotiable requirement for assuring therapeutic quality. At ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback